FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,276 letters match. Newest first.

  1. Yangzhou Sion Commodity Co., Ltd.

    FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.

    High risk
  2. Annovex Pharma, Inc.

    FDA warns outsourcing facility Annovex Pharma in Lorton, VA, over contaminated sterile drug production and missed FDA reports.

    High risk
  3. Aspen Biopharma Labs Private Limited

    FDA warns Aspen Biopharma Labs over current good manufacturing practice failures in active ingredient manufacturing after U.S. recall.

    High risk
  4. Hangzhou Glamcos Biotech Co., Ltd.

    Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.

    High risk
  5. Advanced Pharmaceutical Technology

    FDA warns Advanced Pharmaceutical Technology over drug manufacturing quality failures, sterility controls, and unapproved drugs.

    High risk
  6. Neva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi

    FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.

    High risk
  7. Kabana Skin Care

    FDA warned Kabana Skin Care that its "Kabana Body Wash +UV" is an unapproved, misbranded sunscreen drug sold without required FDA clearance.

    Medium
  8. Waxhead Sun Defense Company

    FDA warned Waxhead Sun Defense Company that its zinc body wash/shampoo is an unapproved, misbranded OTC sunscreen drug.

    Medium
  9. CoLabs Intl. Corp

    CoLabs Intl. Corp marketed KLĒNSKIN WASH ON SUNSCREEN, an OTC sunscreen wash, without an FDA-approved application or authorized dosage form.

    Medium
  10. International Laboratories Corp

    FDA warned International Laboratories Corp, a Thai drug manufacturer, over fabricated lab records and inadequate CGMP controls.

    High risk
  11. Mehran Michael Bahrami, M.D.

    FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.

    High risk
  12. Aspen Pharmacare Holdings Limited

    FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.

    High risk
  13. Rite-Kem Incorporated

    FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.

    High risk
  14. Vegewax Candleworx Ltd.

    FDA warns Vegewax Candleworx over CGMP violations in OTC drug manufacturing, including inadequate component testing and OOS investigations.

    High risk
  15. Pico IV Inc.

    FDA warned Pico IV Inc. that its intravenous CBD product Pico IV is an unapproved new drug sold with drug claims.

    High risk
  16. C & A Naturistics

    C & A Naturistics sold unapproved new drugs online, including AK Forte with hidden acetaminophen and diclofenac.

    High risk
  17. Filler Lux dba Filler Lux USA

    FDA warned Filler Lux USA that it sells unapproved injectable lipolytic drugs online without FDA approval.

    High risk
  18. Fox Pharma LLC

    FDA warned Fox Pharma LLC that it sells unapproved injectable lipolytic drugs online.

    High risk
  19. Hyaluron Pen Store, LLC dba Glow Nest Beauty

    Glow Nest Beauty sells unapproved injectable fat-dissolving drugs online, FDA warned.

    High risk
  20. Julian Naya Beauty LLC

    FDA warned Julian Naya Beauty LLC that it sells six unapproved injectable fat-dissolving drugs on its website and social media.

    High risk
  21. Vivid-Scientific LLC

    Vivid-Scientific LLC sold injectable fat-dissolving products online as unapproved new drugs without FDA-approved applications.

    High risk
  22. Amazon.com, Inc.

    FDA warned Amazon over selling unapproved injectable fat-dissolving drugs on its website.

    High risk
  23. Shree Jaya Laboratories PVT. LTD.

    FDA warned Shree Jaya Laboratories after an inspection found CGMP deviations in API and intermediate manufacturing, including dirty equipment and torn batch records.

    High risk
  24. USApeptide.com

    FDA warns Germany-based USApeptide.com that it sells unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers online.

    High risk
  25. Linghai ZhanWang Biotechnology Co., Ltd

    Linghai ZhanWang Biotechnology's OTC drugs, including antimicrobial wipes, fail manufacturing quality rules; FDA cites missing tests.

    High risk
  26. Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals

    FDA warned outsourcing facility Carie Boyd Pharmaceuticals in Irving, TX that sterile drug production had airflow, media fill and contamination control failures.

    High risk
  27. ProRx, LLC

    FDA warns ProRx, LLC about insanitary sterile compounded-drug production and manufacturing-quality failures.

    High risk
  28. Granules India Limited

    FDA warned Granules India in Telangana, India, that its finished drugs are adulterated after inspectors found cross-contamination in air ducts, bird droppings and torn records.

    High risk
  29. TKTX USA

    FDA warned TKTX USA that its TKTX Numbing Creams are unapproved and misbranded drugs with lidocaine levels above OTC limits.

    High risk
  30. TKTX Numb Store

    FDA warned TKTX Numb Store that its lidocaine anesthetic creams are unapproved and misbranded drugs sold without a prescription.

    High risk
  31. TKTX Store

    FDA warns TKTX Store it sells unapproved lidocaine and prilocaine numbing creams online for tattooing and cosmetic procedures.

    High risk
  32. TKTX Numbing Cream USA

    FDA warned TKTX Numbing Cream USA that its lidocaine numbing creams are unapproved and misbranded new drugs.

    High risk
  33. Chem-Tech, Ltd.

    Chem-Tech, Ltd. lacked adequate investigations and clean equipment for its OTC drug.

    High risk
  34. Zenzi Pharmaceutical Industries Pvt. Ltd.

    Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.

    High risk
  35. Marshalls Traditional Healthcare CC

    Marshalls Traditional Healthcare, an OTC drug maker in South Africa, lacked finished-product release testing and process validation.

    High risk
  36. ABR Laboratory LLC

    FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.

    High risk
  37. Tyche Industries Ltd

    FDA warned Tyche Industries over falsified records, dirty equipment, and untested raw materials at its API plant.

    High risk
  38. Jagsonpal Pharmaceuticals Limited

    Jagsonpal Pharmaceuticals cited for API CGMP and listing failures after Indian inspection, leading to US import alert.

    High risk
  39. AmWiner & Raphe Holdings, LLC dba rapheGenerics Corp

    FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.

    High risk
  40. Chengdu Innovation Pharmaceutical Co., Ltd.

    FDA warned Chengdu Innovation Pharmaceutical over CGMP (manufacturing quality rules) failures in API (drug ingredient) manufacturing, including no identity testing of incoming materials.

    High risk
  41. Wuhu Nuowei Chemistry Co., Ltd.

    FDA cited Wuhu Nuowei Chemistry for API CGMP deviations in impurity testing, stability data, and cleaning, and placed products on import alert.

    High risk
  42. ISOThrive, Inc.

    ISOThrive ran two human studies of a supplement used as a drug without submitting a required IND.

    High risk
  43. Strukmyer LLC dba Strukmyer Medical

    Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.

    High risk
  44. Shantou Kangjie Daily Chemical Industry Co., Ltd

    FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.

    High risk
  45. Imperial Palace Commodity -Dongguan- Co., Ltd.

    FDA warns Chinese maker of OTC alcohol wipes that weak component testing and process validation make its drugs adulterated.

    High risk
  46. Center for Instrumental Analysis of China Pharmaceutical University

    Center for Instrumental Analysis of China Pharmaceutical University cited for incomplete API testing records and no quality unit.

    High risk
  47. Global Calcium Pvt. Limited

    FDA cites Global Calcium API plant for falsified records, deleted files, facility leaks and incomplete impurity profiles; products on Import Alert 66-40.

    High risk
  48. Fagron Compounding Services, LLC dba Fagron Sterile Service

    FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.

    High risk
  49. Kardesler Ucan Yaglar Sanayi Anonim Sirketi

    Turkey-based OTC drug maker Kardesler Ucan failed to test glycerin, propylene glycol and ethanol for dangerous impurities and is on US import alert.

    High risk
  50. Mihon Corp. d/b/a VitalityVita and Boulla, LLC

    FDA warns Mihon Corp./Boulla that VitalityXtra, PeakMax, ZapMax and ZoomMax supplements contain hidden sildenafil and diclofenac and are unapproved, misbranded drugs.

    High risk